Sugi Predict

Sugi Predict / Targets / TYRO3

TYRO3

Tyrosine-protein kinase receptor TYRO3 · Q06418 · TYRO3 on Sugi Atlas →

87,727 patent compounds predicted against TYRO3, 55,387 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL59509 SCHEMBL59509 0.55 14/20
SCHEMBL59311 SCHEMBL59311 0.52 13/20
SCHEMBL59030 SCHEMBL59030 0.44 13/20
SCHEMBL65722 SCHEMBL65722 0.43 13/20
SCHEMBL59352 SCHEMBL59352 0.61 12/20
SCHEMBL59557 SCHEMBL59557 0.55 12/20
SCHEMBL58452 SCHEMBL58452 0.54 12/20
SCHEMBL60028 SCHEMBL60028 0.52 12/20
SCHEMBL58840 SCHEMBL58840 0.52 12/20
SCHEMBL59730 SCHEMBL59730 0.46 12/20
SCHEMBL59111 SCHEMBL59111 0.45 12/20
SCHEMBL57878 SCHEMBL57878 0.44 12/20
SCHEMBL60212 SCHEMBL60212 0.55 11/20
SCHEMBL65796 SCHEMBL65796 0.54 11/20
SCHEMBL65378 SCHEMBL65378 0.52 11/20
SCHEMBL59006 SCHEMBL59006 0.52 11/20
SCHEMBL60066 SCHEMBL60066 0.50 11/20
SCHEMBL58631 SCHEMBL58631 0.49 11/20
SCHEMBL57710 SCHEMBL57710 0.47 11/20
SCHEMBL58546 SCHEMBL58546 0.46 11/20

Clinical trials — most relevant to TYRO3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study PHASE2/PHASE3COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma PHASE2COMPLETED
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy PHASE2WITHDRAWN
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases PHASE2COMPLETED
Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy PHASE2NOT_YET_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) PHASE2RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. PHASE2COMPLETED
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib PHASE1/PHASE2COMPLETED
Fostamatinib for Hospitalized Adults With COVID-19 PHASE2COMPLETED
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC PHASE2ACTIVE_NOT_RECRUITING
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) PHASE2RECRUITING
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies PHASE1COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations PHASE1RECRUITING
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma EARLY_PHASE1RECRUITING
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) nanRECRUITING
The Ameliorative Effect of C-Kit (+) Hepatic Endothelial Cells With Mertk Deficiency on Nonalcoholic Steatohepatitis nanACTIVE_NOT_RECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a TYRO3 binder may also engage these)

ProteinNameSimilarity
P55144 — 0.999 P55144 →
P55146 — 0.999 P55146 →
AXL Tyrosine-protein kinase receptor UFO 0.993 landscape →
Q98949 — 0.991 Q98949 →
A0JM20 — 0.989 A0JM20 →
FGFR4 Fibroblast growth factor receptor 4 0.987 landscape →
Q9YI66 — 0.987 Q9YI66 →
Q00993 — 0.986 Q00993 →
Q03142 — 0.985 Q03142 →
Q498D6 — 0.985 Q498D6 →
Q8QFP9 — 0.984 Q8QFP9 →
FGFR3 Fibroblast growth factor receptor 3 0.982 landscape →
EPHB4 Ephrin type-B receptor 4 0.981 landscape →
EPHA1 Ephrin type-A receptor 1 0.979 landscape →
TNK1 Non-receptor tyrosine-protein kinase TNK1 0.979 landscape →
Q60750 — 0.979 Q60750 →
Q9Z2I4 — 0.979 Q9Z2I4 →
P0C0K6 — 0.978 P0C0K6 →
Q99ML2 — 0.978 Q99ML2 →
Q63474 — 0.978 Q63474 →
Q13308 — 0.978 Q13308 →
P08923 — 0.978 P08923 →
Q03146 — 0.977 Q03146 →
P57097 — 0.977 P57097 →
Q8BYG9 — 0.976 Q8BYG9 →
P51840 — 0.976 P51840 →
CDC42BPG Serine/threonine-protein kinase MRCK gamma 0.976 landscape →
Q8K099 — 0.976 Q8K099 →
DDR1 Epithelial discoidin domain-containing receptor 1 0.976 landscape →
Q06805 — 0.976 Q06805 →